HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Ruxotemitide

HCID 46200994
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
1345407-05-7
Standard SMILES
NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(c1ccccc1)c1ccccc1)C(N)=O
InChIKey
GGAKLYWEFZCVIT-TVEKFXMRSA-N
Molecular formula
C78H106N18O9
Average molar mass
1,439.8 g/mol
Monoisotopic mass
1,438.83901703

Overview

LTX-315 has been used in trials studying the treatment of Cancer, Lymphoma, Melanoma, Carcinoma, and Breast Cancer, among others.

Names & identifiers

Preferred name
Ruxotemitide
IUPAC
(2S)-2,6-diamino-N-[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxo-3,3-diphenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]hexanamide
English name
LTX-315
Molecular formula
C78H106N18O9
Molecular weight
1439.79

Names & synonyms

LTX-3151345407-05-7OncoporeRuxotemitideKkwwkkwdipk-nh2LTX 315ruxotemitida75FBL12IZ7ruxotemitidumRefChem:154173KKWWKKW-BETA-PHENYL-FK-NH2(2S)-2,6-diamino-N-((2S)-6-amino-1-(((2S)-1-(((2S)-1-(((2S)-6-amino-1-(((2S)-6-amino-1-(((2S)-1-(((2S)-1-(((2S)-1,6-diamino-1-oxohexan-2-yl)amino)-1-oxo-3,3-diphenylpropan-2-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-1-oxohexan-2-yl)amino)-1-oxohexan-2-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)amino)-1-oxohexan-2-yl)hexanamide
Show more names
LTX-315?, >98%Ruxotemitide (LTX 315)K-K-W-W-K-K-W-Dip-K-NH2LTX-315,K-K-W-W-K-K-W-Dip-K-NH2Ruxotemitide (LTX 315) TFA saltLTX-315,K-K-W-W-K-K-W-Dip-K-NH2, >98%L-Lysinamide, L-lysyl-L-lysyl-L-tryptophyl-L-tryptophyl-L-lysyl-L-lysyl-L-tryptophyl-β-phenyl-L-phenylalanyl-
Kkwwkkw-.beta.-phenyl-fk-nh2(S)-2,6-diamino-N-((5S,8S,11S,14S,17S,20S,23S,26S)-11,20,23-tris((1H-indol-3-yl)methyl)-1,30-diamino-14,17-bis(4-aminobutyl)-8-benzhydryl-5-carbamoyl-7,10,13,16,19,22,25-heptaoxo-6,9,12,15,18,21,24-heptaazatriacontan-26-yl)hexanamideC78H106N18O9RUXOTEMITIDE [INN]UNII-75FBL12IZ7orb1226499CHEMBL4297628LTX 315 [WHO-DD]

Database identifiers

CAS
1345407-05-7
PubChem CID
46200994
ChEMBL
CHEMBL4297628
UNII
75FBL12IZ7
Nikkaji
J3.769.766D

Properties

Computed structural propertiesFilling in

XLogP
3.6
Topological polar surface area
479 Ų
Hydrogen bond donors
18
Hydrogen bond acceptors
15
Rotatable bonds
46
Heavy atoms
105
Formal charge
0
Complexity
2,670

Physicochemical properties

Boiling point
1700.2 · 1700.2±65.0 °C(Predicted)
Density
1.263 · 1.263±0.06 g/cm3(Predicted)
storage temp.
-20 °C · Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
pka
13.04 · 13.04±0.46(Predicted)
Sequence
2 · H-Lys-Lys-Trp-Trp-Lys-Lys-Trp-Dip-Lys-NH2
FDA UNII
75 FBL12IZ7 · 75FBL12IZ7
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
302 · H302-H315-H319-H335
Precautionary statements
261 · P261-P305+P351+P338

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H302-H315-H319-H335
Precautionary statements
P261-P305+P351+P338

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationRelated reactionsCompound notes